Wenxiu Yao

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 361 citations

Oncology, Pharmacology, Bronchial Neoplasm +5

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 293 citations

Camrelizumab Plus Carboplatin, Medicine, Advanced Squamous Nsclc +8

Liposomal Quercetin Efficiently Suppresses Growth of Solid Tumors in Murine Models

Zhiping Yuan, Lijuan Chen, Linyu Fan et al. · Clinical Cancer Research · 2006 · 250 citations · Full text

Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, D. Ross Camidge, Sang‐We Kim et al. · New England Journal of Medicine · 2024 · 178 citations · Full text

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Hongyun Zhao, Wenxiu Yao, Xuhong Min et al. · Journal of Thoracic Oncology · 2021 · 116 citations

Apatinib Plus Gefitinib, Medicine, Advanced Egfr-mutant Nsclc +8